13 completed, 2 active not recruiting, 2 recruiting. 17 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 13, Active not recruiting 2, Recruiting 2 |
Follow Triapine: new trials by email Literature Review of Triapine trials Research Report on Triapine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy - Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2025-07-30 | 2026-10-21 |
| Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration - Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma | Phase 1 | Recruiting | Northwestern University | 22 | 2024-07-23 | 2026-09-09 |
| Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2020-07-20 | 2026-11-18 |
| Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer Biospecimen Collection, Brachytherapy, Cisplatin - Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2019-09-18 | 2026-11-18 |
| 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery 3-Dimensional Conformal Radiation Therapy, Triapine - Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7 | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-12-20 | 2017-08-18 |
| 3-AP in Treating Patients With Advanced or Metastatic Solid Tumors triapine, pharmacological study, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2006-12-01 | 2013-12-16 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma gemcitabine hydrochloride, triapine - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-06-01 | 2013-09-30 |
| Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies triapine, laboratory biomarker analysis, external beam radiation therapy - Recurrent Cervical Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2006-03-01 | 2013-01-11 |
| Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors triapine, irinotecan hydrochloride, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2004-03-01 | 2013-05-16 |
| 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome fludarabine phosphate, triapine - Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2004-01-01 | 2010-03-10 | |
| 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors triapine, doxorubicin hydrochloride, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2004-01-01 | 2013-05-16 |
| 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies cytarabine, triapine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Completed | National Cancer Institute (NCI) | 48 | 2004-01-01 | 2013-01-24 |
| 3-AP and Cytarabine in Treating Patients With Hematologic Cancer cytarabine, triapine - Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | Vion Pharmaceuticals | 2003-03-01 | 2013-07-18 | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer cisplatin, triapine - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Vion Pharmaceuticals | 2001-03-01 | 2013-07-18 | |
| 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer cisplatin, paclitaxel, triapine - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Vion Pharmaceuticals | 2000-12-01 | 2013-07-18 | |
| 3-AP in Treating Patients With Advanced Cancer triapine - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Vion Pharmaceuticals | 2000-05-01 | 2013-07-18 | |
| 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors triapine - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Vion Pharmaceuticals | 1998-05-01 | 2013-07-18 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Blast Crisis (3) · Congenital Abnormalities (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myeloid, Acute (3) · Anemia, Refractory, with Excess of Blasts (2) · Glioblastoma (2) · Leukemia (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (2) · Leukemia, Myelomonocytic, Chronic (2) · Lymphoma, Follicular (2) · Myelodysplastic Syndromes (2) · Myelodysplastic-Myeloproliferative Diseases (2) · Myeloproliferative Disorders (2)
National Cancer Institute (NCI) (10) · Vion Pharmaceuticals (5) · Northwestern University (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (17)
Mario Sznol, MD (5) · George Wilding (2) · Tanios Bekaii-Saab (2) · Charles Kunos (1) · Judith E. Karp, MD (1) · Karan Dixit, MD (1) · Olatoyosi Odenike (1) · Sarah E Taylor (1) · Stephanie M Yoon (1) · Susanne M Arnold (1) · Yun Yen (1)
PMID 17640728, PMID 27878356, PMID 39673591, PMID 42518206
U01CA062491 (2), U01CA076576 (2), P30CA006973 (1), P30CA014520 (1), P30CA016058 (1), P30CA060553 (1), U01CA062502 (1), U01CA062505 (1), U01CA069852 (1), U01CA070095 (1), UM1CA186690 (1), UM1CA186712 (1), UM1CA186717 (1)